...
ilmn-img

Illumina Inc, Common Stock

ILMN

NSQ

$124.46

+$4.21

(3.5%)

1D
Industry: Life Sciences Tools & Services Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$19.82B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
NM
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.30M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
1.52M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.19
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$89 L
$217.6 H
$124.46

About Illumina Inc, Common Stock

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California. more

Industry: Life Sciences Tools & ServicesSector: Health Care

Returns

Time FrameILMNSectorS&P500
1-Week Return5.75%1.89%-0.81%
1-Month Return-7.16%-2.71%-3.95%
3-Month Return-11.57%1.31%3.35%
6-Month Return4.18%11.93%19.7%
1-Year Return-45.67%6.35%22.93%
3-Year Return-70.01%19.71%25.5%
5-Year Return-61.36%76.38%85.41%
10-Year Return-19.02%186.71%221.1%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue3.54B3.24B4.53B4.58B4.50B[{"date":"2019-12-31","value":77.29,"profit":true},{"date":"2020-12-31","value":70.66,"profit":true},{"date":"2021-12-31","value":98.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.25,"profit":true}]
Cost of Revenue1.08B1.04B1.37B1.61B1.76B[{"date":"2019-12-31","value":61.14,"profit":true},{"date":"2020-12-31","value":58.86,"profit":true},{"date":"2021-12-31","value":77.95,"profit":true},{"date":"2022-12-31","value":91.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit2.47B2.20B3.15B2.97B2.74B[{"date":"2019-12-31","value":78.22,"profit":true},{"date":"2020-12-31","value":69.85,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.23,"profit":true},{"date":"2023-12-31","value":87,"profit":true}]
Gross Margin69.63%68.01%69.69%64.83%60.92%[{"date":"2019-12-31","value":99.92,"profit":true},{"date":"2020-12-31","value":97.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.04,"profit":true},{"date":"2023-12-31","value":87.43,"profit":true}]
Operating Expenses1.48B1.62B3.28B7.15B2.97B[{"date":"2019-12-31","value":20.72,"profit":true},{"date":"2020-12-31","value":22.7,"profit":true},{"date":"2021-12-31","value":45.83,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.48,"profit":true}]
Operating Income985.00M393.00M(123.00M)(4.18B)(1.07B)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.9,"profit":true},{"date":"2021-12-31","value":-12.49,"profit":false},{"date":"2022-12-31","value":-424.26,"profit":false},{"date":"2023-12-31","value":-108.53,"profit":false}]
Total Non-Operating Income/Expense156.00M455.00M946.00M(8.84B)(67.00M)[{"date":"2019-12-31","value":16.49,"profit":true},{"date":"2020-12-31","value":48.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-934.88,"profit":false},{"date":"2023-12-31","value":-7.08,"profit":false}]
Pre-Tax Income1.12B856.00M884.00M(4.34B)(1.12B)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":76.57,"profit":true},{"date":"2021-12-31","value":79.07,"profit":true},{"date":"2022-12-31","value":-387.84,"profit":false},{"date":"2023-12-31","value":-99.91,"profit":false}]
Income Taxes128.00M200.00M122.00M68.00M44.00M[{"date":"2019-12-31","value":64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":61,"profit":true},{"date":"2022-12-31","value":34,"profit":true},{"date":"2023-12-31","value":22,"profit":true}]
Income After Taxes990.00M656.00M762.00M(4.40B)(1.16B)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":66.26,"profit":true},{"date":"2021-12-31","value":76.97,"profit":true},{"date":"2022-12-31","value":-444.85,"profit":false},{"date":"2023-12-31","value":-117.27,"profit":false}]
Income From Continuous Operations990.00M656.00M762.00M(4.40B)(1.16B)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":66.26,"profit":true},{"date":"2021-12-31","value":76.97,"profit":true},{"date":"2022-12-31","value":-444.85,"profit":false},{"date":"2023-12-31","value":-117.27,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income1.00B656.00M762.00M(4.40B)(1.16B)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":65.47,"profit":true},{"date":"2021-12-31","value":76.05,"profit":true},{"date":"2022-12-31","value":-439.52,"profit":false},{"date":"2023-12-31","value":-115.87,"profit":false}]
EPS (Diluted)6.584.505.962.120.87[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.39,"profit":true},{"date":"2021-12-31","value":90.58,"profit":true},{"date":"2022-12-31","value":32.22,"profit":true},{"date":"2023-12-31","value":13.22,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ILMN
Cash Ratio 0.67
Current Ratio 1.66
Quick Ratio 1.29

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ILMN
ROA (LTM) -0.53%
ROE (LTM) -18.81%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ILMN
Debt Ratio Lower is generally better. Negative is bad. 0.43
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.57
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 1.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ILMN
Trailing PE NM
Forward PE 129.87
P/S (TTM) 4.49
P/B 3.52
Price/FCF 111
EV/R 4.76
EV/Ebitda NM
PEG NM

News

Illumina: Engineering a Cool Career in Biotech - and Volunteering Along the Way

What kind of opportunities can an engineer find through their work? Plenty, at Illumina! One employee shares how she makes a difference.Originally published on Illumina News Center NORTHAMPTON, MA …

18 Apr, 2024 a 5:38 pm Finanz Nachrichten

Illumina: Evidence Supports Sequencing As First-Line Rare Disease Diagnostic

The Medical Genome Initiative presents a paper in an effort to expand patient access to sequencingOriginally published on Illumina News CenterNORTHAMPTON, MA / ACCESSWIRE / April 17, 2024 / A recen…

17 Apr, 2024 a 1:38 pm Finanz Nachrichten

DNA Test Kits Market is Expected To Witness A Sustainable Growth Over 2031: Devyser, Illumina, Inc., Ancestry, Veritas

DNA Test Kits Market is estimated to be valued at USD 1.86 Bn in 2024 and is expected to reach USD 5.40 Bn by 2031, exhibiting a CAGR of 16.5% from 2024 to 2031 BURLINGAME, CALIFORNIA, UNITED STATES, April 15, 2024 /⁨EINPresswire.com⁩/ -- DNA Test …

16 Apr, 2024 a 6:03 am EIN News Marijuana

European Commission approves Illumina’s divestment plan for GRAIL

The European Commission, exercising its authority under the EU Merger Regulation (EUMR), has granted approval to Illumina’s proposed divestment of GRAIL. This decision, crucial for the restoration of competitive equilibrium in the blood-based early cancer detection market, follows the Commission’s previous order in October 2023 requiring Illumina to reverse its acquisition of GRAIL. The deal […]

14 Apr, 2024 a 3:47 am Business News Today

EU approves Illumina’s plan to divest cancer test maker Grail By Reuters

By Foo Yun Chee BRUSSELS (Reuters) -U.S. gene sequencing company Illumina (NASDAQ:)’s plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but […] The post EU approves Illumina’s plan to divest cancer test maker Grail By Reuters appeared first on TheAdviserMagazine.com .

12 Apr, 2024 a 3:27 pm TheAdviserMagazine.com

Illumina''s Divestment Plan For Grail Receives Approval From European Commission

SAN DIEGO (dpa-AFX) - Friday, Illumina, Inc. (ILMN) announced that its divestment plan for Grail has received approval from the European Commission. The method of divestment has not been finalized…

12 Apr, 2024 a 1:48 pm Finanz Nachrichten

Illumina Gains Approval for GRAIL Divestiture Plans

Illumina (ILMN) has issued an announcement. Illumina, Inc. has received the green light from the European Commission to move forward with its dives…

12 Apr, 2024 a 1:12 pm TipRanks

Illumina''s planned divestment of GRAIL approved by the European Commission

SAN DIEGO, April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC). While this does not mean the method of…

12 Apr, 2024 a 1:00 pm PR Newswire

FAQs

What is Illumina Inc share price today?

Illumina Inc (ILMN) share price today is $124.46

Can Indians buy Illumina Inc shares?

Yes, Indians can buy shares of Illumina Inc (ILMN) on Vested. To buy Illumina Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ILMN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Illumina Inc be purchased?

Yes, you can purchase fractional shares of Illumina Inc (ILMN) via the Vested app. You can start investing in Illumina Inc (ILMN) with a minimum investment of $1.

How to invest in Illumina Inc shares from India?

You can invest in shares of Illumina Inc (ILMN) via Vested in three simple steps:

  • Click on Sign Up or Invest in ILMN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Illumina Inc shares
What is Illumina Inc 52-week high and low stock price?

The 52-week high price of Illumina Inc (ILMN) is $217.6. The 52-week low price of Illumina Inc (ILMN) is $89.

What is Illumina Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Illumina Inc (ILMN) is NM

What is Illumina Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Illumina Inc (ILMN) is 3.52

What is Illumina Inc dividend yield?

The dividend yield of Illumina Inc (ILMN) is 0.00%

What is the Market Cap of Illumina Inc?

The market capitalization of Illumina Inc (ILMN) is $19.82B

What is Illumina Inc’s stock symbol?

The stock symbol (or ticker) of Illumina Inc is ILMN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top